A Two-Stage, Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Adults
Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Warts
Both
Warts
Trial Information
A Two-Stage, Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Adults
Inclusion Criteria:
- Diagnosis of common warts
- Two forms of birth control
Exclusion Criteria:
- Pregnant or breast feeding
- Other types of warts, ie. plantar
- Currently participating in another clinical study
- Chronic viral hepatitis B or C
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment
Outcome Measure:
Clearance of treated wart(s)
Authority:
United States: Food and Drug Administration
Study ID:
1515-RESI
NCT ID:
NCT00117871
Start Date:
October 2004
Completion Date:
Related Keywords:
- Warts
- Warts
- Adults
- Common Warts
- Resiquimod
- Warts
Name | Location |
|---|---|
| Minnesota Clinical Study Center | Fridley, Minnesota 55432 |
